Evidence map›Paper›PMID 25685169›Full record

ArticleAIDS research and therapy2015

Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007-2010) - TASER-S.

Awachana Jiamsakul, Sunee Sirivichayakul, Rossana Ditangco, Ka-Hing Wong, Patrick Ck Li, Jutarat Praparattanapan, Praphan Phanuphak, Edelwisa Segubre-Mercado, Wing-Cheong Yam, Thira Sirisanthana and 3 more

Abstract read
In one paragraph

Article in AIDS research and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Awachana JiamsakulThe Kirby Institute, UNSW Australia, Sydney, Australia.
Sunee SirivichayakulFaculty of Medicine, Chulalongkorn University and HIV-NAT/The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Rossana DitangcoResearch Institute for Tropical Medicine, Manila, Philippines.
Ka-Hing WongIntegrated Treatment Centre, Hong Kong, China.
Patrick Ck LiDepartment of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
Jutarat PraparattanapanResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Praphan PhanuphakFaculty of Medicine, Chulalongkorn University and HIV-NAT/The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Edelwisa Segubre-MercadoResearch Institute for Tropical Medicine, Manila, Philippines.
Wing-Cheong YamDepartment of Microbiology, Queen Mary Hospital, Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Thira SirisanthanaResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
Thida SingtorojTREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand.
Matthew LawThe Kirby Institute, UNSW Australia, Sydney, Australia.
TREAT Asia Studies to Evaluate Resistance – Surveillance Study (TASER-S)

Funding

The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
NIAID NIH HHS U01 AI069907
6 · The paper itself

Abstract

backgroundThe availability of HIV antiretroviral therapy (ART) has been associated with the development of transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia between 2007-2010.

methodsPatients enrolled in the TREAT Asia Studies to Evaluate Resistance - Surveillance Study (TASER-S) were genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.

resultsProportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong: 3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI (0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time across all four clinical settings.

conclusionsThe observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the scale-up of ART at higher CD4 levels.

Indexed as

AsiaDrug resistanceRecent-infectionResource-limitedTransmitted

Identifiers

PMID25685169
PMCPMC4326480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.